Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

One of the few drug trials for a possible long Covid ended in disappointment. But lessons are leading to a second chance.

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Worsening a patient's credit can prevent them from getting a job, renting an apartment, or even paying their outstanding ...

Humana has refiled its lawsuit against the federal government over its Medicare Advantage ratings, with billions of dollars ...

Declining investment in global health surveillance, research, and scientific innovation are happening as the need for vigilance has never been greater, writes Robert C. Gallo.

CASP, the protein structure prediction contest that launched DeepMind’s Alphafold to international fame and a Nobel Prize, ...

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

The Food and Drug Administration on Monday named George Tidmarsh, a longtime biotech executive who has a background in ...

WASHINGTON — President Trump’s major domestic policy law will result in nearly 10 million more people going without health ...

AstraZeneca announced that it will invest $50 billion in the U.S. by 2030, including a multi-billion-dollar manufacturing ...